METASTATIC PROSTATE CANCER
Clinical trials for METASTATIC PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New 6-Month shot shows promise for prostate cancer control
Disease control CompletedThis study tested a single injection of triptorelin pamoate that lasts 6 months in 195 Chinese men with advanced or metastatic prostate cancer. The goal was to lower testosterone to castrate levels, which helps control cancer growth. Results showed the injection effectively reduc…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated May 26, 2026 05:10 UTC
-
Radioactive therapy shows promise for tough prostate cancer
Disease control CompletedThis study tested a radioactive drug (I-131-1095) that targets prostate cancer cells. It included 120 men whose cancer had stopped responding to the drug abiraterone. Some men received the radioactive drug plus enzalutamide, while others got enzalutamide alone. The main goal was …
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE2 • Sponsor: Progenics Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 05:05 UTC
-
Virtual reality hypnosis eases chemo anxiety in prostate cancer study
Symptom relief CompletedThis study tested whether using virtual reality hypnosis during chemotherapy infusions could lower anxiety in men with metastatic prostate cancer. Fifty-three men receiving docetaxel chemotherapy were randomly assigned to either standard care or a virtual reality hypnosis session…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: NA • Sponsor: Saint-Gregoire Private Hospital Center • Aim: Symptom relief
Last updated May 26, 2026 05:02 UTC
-
Can two drugs make prostate cancer scans clearer?
Knowledge-focused CompletedThis study tested whether taking dasatinib alone or with darolutamide for 14 days can change the appearance of PSMA PET scans in men with metastatic prostate cancer. Four men with low PSMA uptake on their scans participated. The goal was to learn more about how PSMA levels change…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE2 • Sponsor: St Vincent's Hospital, Sydney • Aim: Knowledge-focused
Last updated May 18, 2026 12:13 UTC